Table 7 Clinical trials with epigenetics drugs in metabolic disease
From: Epigenetic regulation in metabolic diseases: mechanisms and advances in clinical study
Drug | Disease | Study type | Number of participants | Recruitment status/phase | NCT number |
|---|---|---|---|---|---|
DNMTi | |||||
Hydralazine | T2D | Interventional | 10251 | Phase 3 | NCT00000620 |
HDACi | |||||
Valproic acid | Obesity | Interventional | 22 | Phase 4 | NCT00298857 |
sodium phenylbutyrate | Diabetes | Interventional | 10 | Phase 4 | NCT00533559 |
sodium phenylbutyrate | Diabetes, obesity | Interventional | 101 | Not Applicable | NCT00771901 |
sodium phenylbutyrate | Obese non diabetic | Interventional | 6 | Not Applicable | NCT05028803 |
ricolinostat | Painful Diabetic Peripheral Neuropathy | Interventional | 282 | Phase 2 | NCT03176472 |
HATi | |||||
Curcumin | T2D | Interventional | 200 | Phase 4 | NCT01052597 |
Curcumin | T2D | Interventional | 60 | Phase 4 | NCT04528212 |
Curcumin | T2D | Interventional | 50 | Phase 2/3 | NCT02529969 |
Curcumin | T2D | Interventional | 44 | Not Applicable | NCT02529982 |
Curcumin | T2D, obeisty | Interventional | 15 | Not Applicable | NCT03542240 |
Curcumin | T2D, NAFLD | Interventional | 50 | Phase 2/3 | NCT02908152 |
Curcumin | Prediabetes | Interventional | 142 | Phase 4 | NCT03917784 |
Curcumin | Obesity, NAFLD | Interventional | 39 | Not Applicable | NCT03864783 |
Curcumin | NAFLD | Interventional | 24 | Not Applicable | NCT04315350 |
STAC | |||||
Resveratrol | Prediabetes | Interventional | 42 | Not Applicable | NCT02565979 |
Resveratrol | T2D | Interventional | 20 | Phase 2 | NCT01354977 |
Resveratrol | T2D | Interventional | 22 | Phase 2 | NCT02549924 |
Resveratrol | Prediabetes | Interventional | 15 | Not Applicable | NCT02129595 |
Resveratrol | Gestational diabetes | Interventional | 112 | Phase 4 | NCT01997762 |
Resveratrol | Diabetic nephropathy | Interventional | 60 | Early phase 1 | NCT02704494 |
Resveratrol | Obesity, NAFLD | Interventional | 26 | Not Applicable | NCT01446276 |
Resveratrol | Obesity, osteoporosis | Interventional | 76 | Not Applicable | NCT01412645 |
Resveratrol | NAFLD | Interventional | 50 | Phase 2/3 | NCT02030977 |
antisense oligonucleotide | |||||
ISIS-GCGRRx | T2D | Interventional | 77 | Phase 2 | NCT01885260 |
ISIS-GCGRRx | T2D | Interventional | 79 | Phase 2 | NCT02583919 |
ISIS-GCGRRx | Diabetes | Interventional | 10 | Phase 4 | NCT02824003 |
ISIS 703802 | T2D, NAFLD | Interventional | 105 | Phase 2 | NCT03371355 |
